Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples